CK20 expression, CDX2 expression, K-ras mutation, and goblet cell morphology in a subset of lung adenocarcinomas

被引:76
作者
Yatabe, Y
Koga, T
Mitsudomi, T
Takahashi, T
机构
[1] Aichi Canc Ctr Hosp, Dept Pathol & Mol Diagnost, Nagoya, Aichi 464, Japan
[2] Aichi Canc Ctr Hosp, Dept Thorac Surg, Nagoya, Aichi 464, Japan
[3] Aichi Canc Ctr, Res Inst, Dept Mol Oncol, Nagoya, Aichi 464, Japan
关键词
CK20; CDX2; K-ras; goblet cells; mucinous carcinoma; non-small cell carcinoma;
D O I
10.1002/path.1566
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
There are data in the literature that suggest a close relationship between the expression of CK20 and CDX2, K-ras mutations, and goblet cell morphology. The present study has examined these factors in a cohort of 264 non-small cell lung cancers. Thirteen of 212 adenocarcinomas expressed CK20; 29 expressed CDX2; K-ras mutation was identified in 28; and goblet cell features were present in 19. These four factors correlated with each other in a complex way and therefore a logistic regression model was constructed. Significant correlations were found between CK20 and CDX2 expression, and between K-ras mutation and goblet cell morphology, and there was a marginal correlation between CDX2 immunoreactivity and goblet cell morphology. These four features have also been commonly detected in colorectal, pancreato-biliary, and ovarian mucinous carcinomas, suggesting that these adenocarcinomas may be prototypical, independent of the organ of origin. Furthermore, as high and uniform expression of CDX2 was characteristic of metastatic colorectal cancer, weak and/or focal CDX2 expression should alert surgical pathologists to the possibility of primary lung adenocarcinoma, especially in the presence of goblet cell morphology. However, some lung adenocarcinomas may express CDX2 strongly: in this case, CK20 also tends to be positive. Copyright (C) 2004 Pathological Society of Great Britain and Ireland. Published by John Wiley Sons, Ltd.
引用
收藏
页码:645 / 652
页数:8
相关论文
共 41 条
[1]   Transcriptional accessibility for genes of multiple tissues and hematopoietic lineages is hierarchically controlled during early hematopoiesis [J].
Akashi, K ;
He, X ;
Chen, J ;
Iwasaki, H ;
Niu, C ;
Steenhard, B ;
Zhang, JW ;
Haug, J ;
Li, LH .
BLOOD, 2003, 101 (02) :383-390
[2]   CDX-2 homeobox gene expression is a reliable marker of colorectal adenocarcinoma metastases to the lungs [J].
Barbareschi, M ;
Murer, B ;
Colby, TV ;
Chilosi, M ;
Macri, E ;
Loda, M ;
Doglioni, C .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2003, 27 (02) :141-149
[3]   Identification of the familial cylindromatosis tumour-suppressor gene [J].
Bignell, GR ;
Warren, W ;
Seal, S ;
Takahashi, M ;
Rapley, E ;
Barfoot, R ;
Green, H ;
Brown, C ;
Biggs, PJ ;
Lakhani, SR ;
Jones, C ;
Hansen, J ;
Blair, E ;
Hofmann, B ;
Siebert, R ;
Turner, G ;
Evans, DG ;
Schrander-Stumpel, C ;
Beemer, FA ;
van den Ouweland, A ;
Halley, D ;
Delpech, B ;
Cleveland, MG ;
Leigh, I ;
Leisti, J ;
Rasmussen, S ;
Wallace, MR ;
Fenske, C ;
Banerjee, P ;
Oiso, N ;
Chaggar, R ;
Merrett, S ;
Leonard, N ;
Huber, M ;
Hohl, D ;
Chapman, P ;
Burn, J ;
Swift, S ;
Smith, A ;
Ashworth, A ;
Stratton, MR .
NATURE GENETICS, 2000, 25 (02) :160-165
[4]  
BOS JL, 1989, CANCER RES, V49, P4682
[5]   The malignant capacity of skin tumours induced by expression of a mutant H-ras transgene depends on the cell type targeted [J].
Brown, K ;
Strathdee, D ;
Bryson, S ;
Lambie, W ;
Balmain, A .
CURRENT BIOLOGY, 1998, 8 (09) :516-524
[6]   Cytokeratin 7 and 20 and thyroid transcription factor 1 can help distinguish pulmonary from gastrointestinal carcinoid and pancreatic endocrine tumors [J].
Cai, YC ;
Banner, B ;
Glickman, J ;
Odze, RD .
HUMAN PATHOLOGY, 2001, 32 (10) :1087-1093
[7]   Keratin expression in human tissues and neoplasms [J].
Chu, PG ;
Weiss, LM .
HISTOPATHOLOGY, 2002, 40 (05) :403-439
[8]   Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: A survey of 435 cases [J].
Chu, PG ;
Wu, E ;
Weiss, LM .
MODERN PATHOLOGY, 2000, 13 (09) :962-972
[9]   Immunocytochemical expression of tissue specific transcription factor-1 in lung carcinoma [J].
DiLoreto, C ;
DiLauro, V ;
Puglisi, F ;
Damante, G ;
Fabbro, D ;
Beltrami, CA .
JOURNAL OF CLINICAL PATHOLOGY, 1997, 50 (01) :30-32
[10]   RASSF1A gene inactivation in non-small cell lung cancer and its clinical implication [J].
Endoh, H ;
Yatabe, Y ;
Shmizu, S ;
Tajima, K ;
Kuwano, H ;
Takahashi, T ;
Mitsudomi, T .
INTERNATIONAL JOURNAL OF CANCER, 2003, 106 (01) :45-51